CML – is difficult to monitor and manage using traditional solutions. New RNA-based assays are hitting the market to make ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Researchers at Dana-Farber Cancer ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Its kit for chronic myeloid leukemia (CML) will begin the regulatory approval process with ... Launched by the company in 2021, the LQ Suite Digital PCR platform, based on microdroplet technology, ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by researchers. Professor Hongtae Kim and his research team in the Department of ...

The Food and Drug Administration (FDA) has granted accelerated approval to Scemblix ® (asciminib) for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid ...

The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ResearchAndMarkets.com's offering.This report provides a ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Precision medicines have long been ...